Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$40.24

 0.65 (1.64%)

High$40.43
Low$39.18
Volume755,807
Market Cap$5,640,321,368

05/27/16  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) 05/25/16

Read more

Seattle Genetics to Present at Upcoming Investor Conferences 05/04/16

Read more

Events

UBS Global Healthcare Conference05/24/16 10:30 a.m. ETView eventBank of America Merrill Lynch 2016 Health Care Conference05/11/16 11:20 a.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources